Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

8.76USD
22 Jun 2017
Change (% chg)

-- (--)
Prev Close
$8.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
929,842
52-wk High
$13.38
52-wk Low
$3.11

ARRY.OQ

Chart for ARRY.OQ

About

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $1,496.21
Shares Outstanding(Mil.): 170.80
Dividend: --
Yield (%): --

Financials

  ARRY.OQ Industry Sector
P/E (TTM): -- 246.80 19.12
EPS (TTM): -0.72 -- --
ROI: -69.79 -7.96 -5.05
ROE: -1,738.67 -10.57 -4.29

BRIEF-Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor

* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and South Korea.

May 31 2017

BRIEF-Array Biopharma & Ono Pharmaceutical announce partnership for two Novel Oncology compounds

* Array Biopharma & Ono Pharmaceutical Co Ltd announce license, development & commercialization partnership for 2 Novel Oncology compounds, Binimetinib and Encorafenib

May 31 2017

BRIEF-Array BioPharma and Bristol-Myers Squibb announce strategic collaboration

* Array bioPharma and Bristol-Myers Squibb announce strategic collaboration

May 30 2017

BRIEF-Array BioPharma Q3 loss per share $0.21

* Array biopharma reports financial results for the third quarter of fiscal 2017

May 10 2017

BRIEF-Array Biopharma announces positive top-line results from part 2 of the phase 3 columbus study of binimetinib and encorafenib

* Array Biopharma announces positive top-line results from part 2 of the phase 3 Columbus study of binimetinib and encorafenib for braf-mutant melanoma

May 09 2017

BRIEF-Array Biopharma provides NEMO update

* Array Biopharma Inc - Has withdrawn from U.S. FDA division of oncology products 2 its new drug application (NDA) for binimetinib monotherapy

Mar 19 2017

BRIEF-Array Biopharma reports financial results for Q2 of fiscal 2017

* Array Biopharma reports financial results for the second quarter of fiscal 2017

Feb 09 2017

More From Around the Web

Earnings vs. Estimates